5-溴苊 | 2051-98-1

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 烃类卤化物
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 5-溴苊
• 中文别名: 5-溴苯乙酮
• 英文名称: 5-bromoacenaphthene
• 英文别名: 5-bromo-1,2-dihydroacenaphthylene；5-bromoacenaphthylene；4-bromoacenaphthene
• CAS: 2051-98-1
• 化学式: C₁₂H₉Br
• mdl: MFCD00003809
• 分子量: 233.107
• InChiKey: QALKJGMGKYKMKE-UHFFFAOYSA-N

物化性质

• 熔点：
  54-56 °C(lit.)
• 沸点：
  335 °C(lit.)
• 密度：
  1.4095 (rough estimate)
• 闪点：
  >230 °F
• 溶解度：
  可溶于氯仿、甲醇（少许）
• 保留指数：
  1755
• 稳定性/保质期：

  在常温常压下保持稳定，应避免与不相容的材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2903999090
• 安全说明：
  S24/25
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  密封储存，应存放在阴凉、干燥的仓库中。

SDS

Name:	5-Bromoacenaphthene 94% Material Safety Data Sheet
Synonym:	None Known
CAS:	2051-98-1

Section 1 - Chemical Product MSDS Name:5-Bromoacenaphthene 94% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2051-98-1	5-Bromoacenaphthene	94%	218-138-7

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate general or local exhaust ventilation to keep airborne concentrations below the permissible exposure limits.
Exposure Limits CAS# 2051-98-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: yellow
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 335 deg C @ 760.00mm Hg
Freezing/Melting Point: 50.00 - 54.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: > 110 deg C (> 230.00 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H9Br
Molecular Weight: 233.11

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2051-98-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Bromoacenaphthene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 2051-98-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2051-98-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2051-98-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴苊 在 sodium hydroxide 、 potassium permanganate 、 sodium dithionite 、 sodium dichromate 、 硝酸 、 乙酸酐 作用下， 以 溶剂黄146 为溶剂， 生成 1,2,3-苯三甲酸
  参考文献：
  名称：

  Petrenko,G.P. et al., Journal of Organic Chemistry USSR (English Translation), 1968, vol. 4, p. 2113 - 2116

  摘要：

  DOI：
• 作为产物：
  描述：

  4-溴-1,8-萘二甲酸酐 在 lithium aluminium tetrahydride 、 乙醚 、 三溴化磷 、 苯 作用下， 生成 5-溴苊
  参考文献：
  名称：

  A New Synthesis of Acenaphthene

  摘要：

  DOI：

  10.1021/ja01107a501

文献信息

• Synthesis of Aromatic Carboxylic Acids by Carbonylation of Aryl Halides in the Presence of Epoxide-Modified Cobalt Carbonyls as Catalysts
  作者：V. P. Boyarskii、T. E. Zhesko、S. A. Lanina

  DOI：10.1007/s11167-005-0619-y

  日期：2005.11

  A new procedure was developed for synthesis of aromatic and heteroaromatic acids and their derivatives (esters, salts) by carbonylation of the corresponding aryl halides. The acids are selectively formed in a high yield under very mild conditions. Highly active catalytic systems, base-containing alcoholic solutions of cobalt carbonyl modified with epoxides, were used to activate aryl halides.

  开发了一种新方法，用于通过相应的芳基卤化物的羰基化合成芳族和杂芳族酸及其衍生物（酯，盐）。在非常温和的条件下可以高产率选择性地形成酸。高活性的催化体系（用环氧化物改性的含羰基钴钴的含碱醇溶液）用于活化芳基卤化物。
• A convenient procedure for the synthesis of 1-tetralone derivatives using a Suzuki coupling-Friedel-Crafts acylation sequence
  作者：Gemma Esteban、Miguel A. López-Sánchez、MaEugenia Martínez、Joaquín Plumet

  DOI：10.1016/s0040-4020(97)10270-8

  日期：1998.1

  The reported 1-tetralone derivatives have been synthesized from arylbromides using as key steps a Suzuki coupling followed by intramolecular Friedel-Crafts acylation.

  已报道的1-四氢萘酮衍生物是使用Suzuki偶联作为随后的分子内Friedel-Crafts酰化反应的关键步骤，由芳基溴化物合成的。
• PHOTOACID GENERATOR, AND RESIN COMPOSITION FOR PHOTOLITHOGRAPHY
  申请人：SAN-APRO LTD.

  公开号：US20160368879A1

  公开（公告）日：2016-12-22

  Provided is a non-ionic photoacid generator (A) expressed by general formula (1). R1 and R2 each independently represents an alkyl group having 1-18 carbons or a fluoroalkyl group having 1-18 carbons, an alkenyl group having 2-18 carbons, an alkynyl group having 2-18 carbons, an aryl group having 6-18 carbons, a silyl group, or the like; m and n respectively represent the number of R1s and R2s, each number being an integer from 0 to 3, and the total number (m+n) of R1s and R2s being an integer from 1 to 6. The m number of R1s and the n number of R2s may each be the same or different. R3 represents a hydrocarbon having 1-18 carbons wherein one part or all of the hydrogen may be substituted by fluorine.

  提供的非离子光酸发生剂（A）由通式（1）表示。R1和R2分别独立表示具有1-18个碳原子的烷基基团或具有1-18个碳原子的氟烷基基团，具有2-18个碳原子的烯基基团，具有2-18个碳原子的炔基基团，具有6-18个碳原子的芳基基团，硅基团等；m和n分别表示R1和R2的数量，每个数字为0到3的整数，R1和R2的总数（m+n）为1到6的整数。R1的数量m和R2的数量n可以相同也可以不同。R3表示具有1-18个碳原子的碳氢化合物，其中氢的一部分或全部可以被氟取代。
• Protease inhibitors
  申请人：——

  公开号：US20020049316A1

  公开（公告）日：2002-04-25

  The present invention provides compounds of formula (I) which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy; and metabolic bone disease therewith.

  本发明提供了一种公式（I）的化合物，其抑制蛋白酶，包括卡特普辛K，以及这些化合物的药物组合物，以及治疗骨量过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说是骨关节炎和类风湿关节炎；帕吉特病；高钙血症或恶性肿瘤；以及代谢性骨病。
• Substituted phenyl farnesyltransferase inhibitors
  申请人：——

  公开号：US20020019527A1

  公开（公告）日：2002-02-14

  Compounds of formula (I) 1 or pharmaceutically acceptable salts thereof, inhibit farnesyltransferase. Methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

  式(I)的化合物或其药学上可接受的盐，抑制法尼基转移酶。公开了制备这些化合物的方法，含有这些化合物的药物组合物，以及使用这些化合物进行治疗的方法。

表征谱图